- Silo Pharma Inc (NASDAQ:SILO) entered into an agreement with Columbia University under which Silo has been granted an extension for its option to license certain assets currently under development, including Alzheimer’s disease and Stress-Induced Anxiety.
- “The first steps of our research with Columbia have been positive and we’re happy to extend this research and option pact to continue the progress of SPC-14 as an Alzheimer’s therapeutic and SPC-15 for Stress Induced Anxiety disorders,” said Eric Weisblum, CEO of Silo Pharma.
- The extension to the agreement incorporates the work of Dr. Christine Ann Denny, an Associate Professor of Clinical Neurobiology (in Psychiatry) at Columbia University Irving Medical Center.
- Denny and her team focus on the molecular mechanisms underlying learning and memory, including Alzheimer’s disease.
- Silo is currently conducting ongoing research studies and looks forward to sharing these results as data becomes available.
- Price Action: SILO shares are trading higher by 0.68% at $5.04 on the last check Tuesday.
FirstService Declares Increase To Quarterly Cash Dividend From $0.225 To $0.25 Per Share
FirstService Corporation (TSX:FSV, NASDAQ:FSV) ("FirstService") announced today that its Board of Directors has approved an 11% increase in the quarterly cash dividend on the outstanding Common Shares of the Company over
